MDxHealth SA — Cyborg Score 5/10

Mixed
Precision Diagnostics / Molecular Diagnostics

Strategic Profile

Headquartered in Belgium with significant U.S. operations, the company has successfully transitioned into a commercial-stage powerhouse focused on urologic cancers. MDxHealth signed a definitive agreement to acquire the business of Exosome Diagnostics, Inc. for $15 million (August 2025), with $5 million in stock at closing and $2.5 million annually over the following 4 years, and completed the acquisition on September 15, 2025.

Cyborg Score Rationale

The company has a market cap of approximately $39.5 million as of August 2026, with negative earnings (EPS of -0.65). Analysts expect the company to break even for the first time, with consensus forecasts suggesting losses will reduce by 36% per year to 2026. The company is in a critical transition phase toward profitability with expanding commercial capabilities.

Top Insights

  • Core product portfolio includes Select mdx (non-invasive urine test for prostate cancer), Confirm mdx (tissue test for occult prostate cancer detection), Resolve mdx (personalized antibiotic selection for UTI), and Genomic Prostate Score (personalized genomic insights).
  • Company reaffirmed full year 2025 revenue guidance of $108 million to $110 million (as of late 2025).
  • Analysts covering the stock expect the company to achieve first-time profitability and project approximately $2.35 million profit by 2027.
  • MDxHealth has 312 full-time employees.

Named Competitors

  • Myriad Genetics — Leading precision diagnostics with oncology focus
  • CareDx — Molecular diagnostics for organ transplant monitoring
  • NeoGenomics — Cancer diagnostics and genomic analysis
  • Labcorp Holdings — Clinical laboratory and molecular diagnostics

Recent Developments

  • (August 2025) Signed definitive agreement to acquire Exosome Diagnostics business for $15 million
  • (September 2025) Completed acquisition of Exosome Diagnostics business
  • (May 2026) William Blair downgraded MDxHealth from Outperform to Market Perform
  • (May 2026) Q1 2026 earnings release reported

Open the full interactive MDxHealth SA report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →